December 1, 2000 - Novartis Warns Of Fatal Risks With Serentil
Dear Doctor or Pharmacist:
On October 11, 2000, The FDA issued a health professionals' letter from Novartis alerting them to a new boxed warning for Serentil (mesoridazine besylate) saying it "has been shown to prolong the QTc interval in a dose-related manner, and drugs with this potential, including Serentil, have been associated with torsade de pointes-type arrhythmias and sudden death."
The drug is now indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects.
If you or a loved one has suffered an injury as a result of taking any drug or supplement, call Law Office of Michael J. Riehm now at 866-886-8757 or CLICK HERE TO SUBMIT A SIMPLE CASE FORM. The initial consultation is free of charge, and if we agree to review your case, we will work on a contingent fee basis, which means we get paid for our services only if there is a monetary award or recovery of funds. Don't delay! You may have a valid claim and be entitled to compensation for your injuries, but a lawsuit must be filed before the statute of limitations expires.
<< back
The above is not legal advice. That can only come from a qualified attorney who is familiar with all the facts and circumstances of a particular, specific case and the relevant law. See Terms of Use.
